"THE PROGNOSTIC SIGNIFICANCE OF INVASION AND MARKERS OF PROLIFERATION IN PATIENTS WITH MACRO AND GIANT INACTIVE PITUITARY TUMORS"
Keywords:
NFPA, giant pituitary adenomasAbstract
Relevance. The assessment of the KI-67 and P53 using immunohistochemistry, usually with monoclonal antibodies of MIB1, is mandatory for evaluating proliferation in patients subjected to transnasal adenomectomy of the pituitary gland.
Goal. To study the prognostic significance of invasion and markers of proliferation in patients with macro and giant inactive pituitary tumors.
Material and methods. In total, 272 patients with macro and giant naga were examined. Of the 272 patients with the naga in the study, 151 patients (men and women) took part in the study)
Research methods included: 1) general clinical (study of endocrine, neurological statuses), 2) instrumental (perimetry for all colors, eye bottom, visual acuity, 3) ECG, CT/MRI of the Turkish saddle and adrenal glands, 4) ultrasound of the internal and genitals, etc.), 5) hormonal blood tests (STG, IFR-1, LG, FSG, PRL, TSL, ACTH, prolactin, testosterone, estradiol, progesterone, cortisol and immunohymph hand-chemical studies.
Results. The observed frequency of immunoexpression of proliferation markers was 40%/50% for P53 (≥3+), 50%/60% for Ki-67 (≥2+). Tumors with immunoexpression of at least 2 markers with a high proliferation index were observed in 54% cohorts and regarded as proliferative adenomas.
Conclusion. Giant inactive pituitary adenomas of the pituitary gland are often accompanied by invasive growth in the surrounding anatomical structures (more than 80% of cases), which is the main factor that limits the radicality of surgical intervention and increases the number of relapses.
References
Botelho C. H. A., De Magalhães A. V., De Mello P. A., Schmitt F. C., Casulari L. A. Expression of p53, KI-67 and c-erb B2 in growth hormone- and/or prolactin-secreting pituitary adenomas. //Arquivos de Neuro-Psiquiatria. 2006;64(1):60–66. doi: 10.1590/S0004- 282X2006000100013.
Buchfelder M. Management of aggressive pituitary adenomas: current treatment strategies. //Pituitary. 2009;12(3):256–260. doi: 10.1007/s11102-008-0153-z.
Central brain tumor registry of the United States 2007-2008. Central Brain Tumor Registry of the United States Statistical Report. 2008
Cottier J.-P., Destrieux C., Brunereau L., et al. Cavernous sinus invasion by pituitary adenoma: MR imaging. //Radiology. 2000;215(2):463–469.
doi: 10.1148/radiology.215.2.r00ap18463.
Edal A. L., Skjödt K., Nepper-Rasmussen H. J. SIPAP—a new MR classification for pituitary adenomas. Suprasellar, infrasellar, parasellar, anterior and posterior. //Acta Radiologica. 1997;38(1):30–36. doi: 10.1080/02841859709171238.
Ferreira J. E. A., de Mello P. A., de Magalhães A. V., et al. Caracterização clínica e imunoistoquímica dos adenomas clinicamente nao-funcionantes de hipófise. //Arquivos de Neuro-Psiquiatria. 2005;63(4):1070–1078. doi: 10.1590/s0004-282x2005000600029.
Jefferson G. Extrasellar extensions of pituitary adenomas. // Proceedings of the Royal Society of Medicine. 1940;33:433–458.
Jefferson G. The Invasive Adenomas of the Anterior Pituitary. 2nd. Springfield, Ill, USA: Charles C. Thomas; 1972.
Knosp E., Steiner E., Kitz K., Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. //Neurosurgery. 1993;33(4):610–618. doi: 10.1227/00006123-199310000-00008.
Kovacs K., Horvath E. Pathology of pituitary tumors. // Endocrinology and Metabolism Clinics of North America. 1987;16(3):529–551.
Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, Drouin J. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. // Cell. 2001;104(6):849–859. doi: 10.1016/S0092-8674(01)00282-3.
Lloyd R. V., Kovacs K., Young W. F., Jr., et al. Pituitary tumours: introduction. In: DeLellis
R. A., Lloyd R. V., Heitz P. U., Eng C., editors. //Tumours of the Pituitary, Chapter 1. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, Paris: World Hearth Organization Classification of Tumours. IARC Press; 2004. pp. 10–13
Mccormack A. I., Wass J. A. H., Grossman A. B. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. // European Journal of Clinical Investigation. 2011;41(10):1133–1148. doi: 10.1111/j.1365-2362.2011.02520.x.
Molitch, M. E. Pituitary incidentalomas //Endocr metab clin north am.- 2013. Vol. 26. - P. 725- 740.
Nagasaka ,T. / Sarcomatous transformation of pituitary adenoma after bromocriptine therapy.
// Hum pathol. -1998.-Vol. 29, №2.-P. 3-190.
Newton, D. R. Management of pituitary adenomas // FJ.N.R. 2009. - Vol. 10. - P. 949-954.
Nishioka H1, Hara T2, Nagata Y3, et all/Inherent Tumor Characteristics That Limit Effective and Safe Resection of Giant Nonfunctioning Pituitary Adenomas. //World Neurosurg. 2017 Oct;106:645-652. doi: 10.1016/j.wneu.2017.07.043. Epub 2017 Jul 19.)
Pulichino AM, Vallette-Kasic S, Tsai JP, Couture C, Gauthier Y, Drouin J. Tpit determines alternate fates during pituitary cell differentiation. //Genes Dev. 2003;17(6):738–747. doi: 10.1101/gad.1065703.
Raverot G., Castinetti F., Jouanneau E., et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. // Clinical Endocrinology. 2012;76(6):769–775. doi: 10.1111/j.1365-2265.2012.04381.x.
Trouillas J., Roy P., Sturm N., et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. //Acta Neuropathologica. 2013;126(1):123–135. doi: 10.1007/s00401-013-1084-y
Zakir JC1, Casulari LA1, Rosa JW2, et all/Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up. //Int J Endocrinol. 2016;2016:7964523. doi: 10.1155/2016/7964523. Epub 2016 Aug 18)
Zemmoura I., Wierinckx A., Vasiljevic A., Jan M., Trouillas J., François P. Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. //Pituitary. 2013;16(4):515–522. doi: 10.1007/s11102-012-0448-y
